Beneficial Effect of Sodium-Glucose Co-transporter 2 Inhibitors on Left Ventricular Function
Background
Sodium-glucose cotransporter 2 (SGLT2) inhibitors lowered the risk of cardiovascular events in patients with diabetes or heart failure (HF) with reduced ejection fraction, whether they directly promote cardiac function remains unclear. Therefore, we sought to determine whether SGLT2 inhibitors could improve left ventricular (LV) function in these patients.
Methods
A literature search was conducted using MEDLINE, EMBASE, and Cochrane Library databases from their inception to July 9, 2021. Randomized clinical trials and cohort studies that reported LV function-related variables were included.
Results
Thirteen studies comprising 1437 patients (830 SGLT2 inhibitor-treated and 607 non-SGLT2 inhibitor-treated patients) and representing 7 randomized controlled trials with 640 individuals and 6 cohort studies with 797 individuals were included in this meta-analysis. LV regression [LV mass (LVM)], LV ejection fractions (LVEF), LV volumes [LV end-diastolic volumes and systolic volumes (LVEDV and LVESV, respectively], and LV diastolic function [mitral inflow E velocity to tissue Doppler e’ ratio, E/e’ and left atrial volume index (LAVI)] were all significantly improved in patients treated with SGLT2 inhibitors (weighted mean differences, 95% CI, LVM: −6.319 g, −10.850 to −1.789; LVEF: 2.458%, 0.693 to 4.224; LVEDV: −9.134 mL, −15.808 to −2.460; LVESV: −8.440 mL, −15.093 to −1.787; LAVI: −2.791 mL/m2, −.554 to −1.027; E/e’: −1.567, −2.440 to −0.698). Subgroup analysis further confirmed the improvement of LV function mainly in patients with HF or those receiving empagliflozin treatment.
Conclusions
Treatment with SGLT2 inhibitors can significantly improve LV function in patients with or without diabetes (especially those with HF or undergoing empagliflozin treatment).
Top-30
Journals
|
1
|
|
|
Frontiers in Cardiovascular Medicine
1 publication, 7.69%
|
|
|
Life
1 publication, 7.69%
|
|
|
Diabetes, Obesity and Metabolism
1 publication, 7.69%
|
|
|
European Journal of Heart Failure
1 publication, 7.69%
|
|
|
Cardiovascular Diabetology
1 publication, 7.69%
|
|
|
Frontiers in Endocrinology
1 publication, 7.69%
|
|
|
Medicine (United States)
1 publication, 7.69%
|
|
|
ESC heart failure
1 publication, 7.69%
|
|
|
Scientific Reports
1 publication, 7.69%
|
|
|
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
1 publication, 7.69%
|
|
|
Clinical Endocrinology
1 publication, 7.69%
|
|
|
Journal of Cardiovascular Electrophysiology
1 publication, 7.69%
|
|
|
International Journal of Clinical Pharmacy
1 publication, 7.69%
|
|
|
1
|
Publishers
|
1
2
3
4
5
|
|
|
Wiley
5 publications, 38.46%
|
|
|
Springer Nature
3 publications, 23.08%
|
|
|
Frontiers Media S.A.
2 publications, 15.38%
|
|
|
MDPI
1 publication, 7.69%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
1 publication, 7.69%
|
|
|
Taylor & Francis
1 publication, 7.69%
|
|
|
1
2
3
4
5
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.